Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
High Frequency of Braf V600e Mutation in Iranian Population Ameloblastomas Publisher Pubmed



Derakhshan S1 ; Aminishakib P1 ; Karimi A2 ; Saffar H3 ; Abdollahi A4 ; Mohammadpour H5 ; Fard MJK6 ; Memarha A7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Oral and Maxillofacial Pathology Department, School of Dentistry, Tehran University of Medical Sciences, Iran
  2. 2. Oral and Maxillofacial Surgery Department, School of Dentistry, Shariati Hospital, Craniomaxillofacial Research Center, Tehran University of Medical Sciences, Iran
  3. 3. Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Iran
  4. 4. Department of Pathology, Imam Hospital Complex, Cancer institute, Tehran University of Medical Sciences, Iran
  5. 5. Iran National Tumor Bank, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Iran
  6. 6. Dental Research Center, School of Dentistry, Tehran University of Medical Sciences, Iran
  7. 7. School of Dentistry, Tehran University of Medical Sciences, Iran

Source: Medicina Oral Patologia Oral y Cirugia Bucal Published:2020


Abstract

Background: Ameloblastoma is a common locally invasive but slow-growing neoplasm of the jaws with an odontogenic origin. Association between BRAF V600E mutation and clinicopathologic features and behavior of ameloblastoma remains controversial. This study aimed to evaluate BRAF V600E gene mutation and expression of its related proteins with clinicopathologic parameters in conventional ameloblastoma. Material and Methods: 50 Formalin-fixed paraffin-embedded blocks were included in this study. Immunohistochem-istry was done using rabbit monoclonal BRAF V600E mutation-specific antibody VE1. Quantitative real-time polymerase chain reaction assay was used for evaluating of BRAF V600E mutation. Results: Expression of BRAF V600E antibody was Positive in 42 out of 50 cases (84%). 46 (92%) out of 50 specimens showed BRAF V600E mutation. There were 13 cases of recurrence (26%). 3 out of 4 cases with negative mutations did not show recurrence. Conclusions: We report the highest frequency (92%) of BRAF V600E mutation in ameloblastomas in the Iranian population. Although there was not a significant association between BRAF V600E-positive immunoexpression and recurrence and clinicopathologic parameters, its high frequency could emphasize its role as a therapeutic marker in the future. © Medicina Oral S. L. C.I.F. B.